NewStem’s diagnostic kit can predict resistance to chemotherapy

Post published:July 15, 2017

The breakthrough diagnostic kit under development by NewStem can predict if a tumor will develop resistance to drugs, making therapy ineffective. The technology is based on research of Prof. Nissim Benvenisty at the Hebrew University of Jerusalem and was acquired under an exclusive license from Yissum Research Development Company, university’s the technology-transfer company. NewStem’s CEO is Ayelet Dilion-Mashiah.

For more information, see:
https://www.israel21c.org/new-technology-can-predict-resistance-to-chemotherapy/

Government Non-Dilutive Funding for Bio Startups
Wednesday, June 14th, 2023
For more information and to register, click here.

More JLM-BioCity events coming soon…

Alexander Naslednikov

Excellent organization (from the timing to food), the quality of the audience was superior, we personally got a lot of hot leads.

-Alexander Naslednikov, Founder and CEO, Med.me

Tal Or

One of the best meetups organizations and a very important source of information and connections for startups.

-Tal Or, Co-Founder, ATLASense Biomed Ltd.

Hemda Idel

Very informative and eye-opening event. Thank you for the great hospitality.

– Hemda Idel, founder, SLEEP ASAP

Aviv Marom

There was an excellent networking atmosphere with impressive Panelists as well as high-quality audience participants. I strongly recommend paying attention to future events.

-Aviv Marom, Director, Strategic Partnerships, Samsung Research, Israel

Aurélie Schwarzbach

Such an interesting lecture and great people attending!

– Aurélie Schwarzbach, Clinical Project Manager, Gamida Cell Ltd.

Zeev Malyutin

Thank you all for the great evening, it was a pleasure to see such a good and diverse set of Biomed minded people in Jerusalem!

– Zeev Malyutin, Protein Department Head, Merck KGaA

Gideon Silberman

Excellent event. Good speakers, interesting audience. Well done!

– Gideon Silberman, Director of Business Development, Partner and Co-Founder, Aneeva.com

Immanuel Lerner

I believe in the idea of JLM-BioCity. It is good that there is an organization that represents the life science companies in Jerusalem and provides an excellent platform for networking through its regular meetings.

– Immanuel Lerner CEO, Pepticom

Dror Chevion

JLM-BioCity’s events are well organized with a professional approach. You can feel a “homey” atmosphere around the people of a well-maintained bio-community in Jerusalem. Team members always make sure the guests feel welcome and connected to the right people for possible collaborations. There are clearly visible good-will and dedication to lead the members of the bio-community and the city as a whole to success.

– Dror Chevion CEO, Concenter BioPharma

Ian Solomon

The JLM BioCity networking events on Zoom keeps getting better. For OmnySense they have provided an excellent forum in which to present our company, and the break-out sessions facilitate direct discussion with a broad range of potential partners and investors.

-Ian Solomon CTO, OmnySense Ltd.

Moshe Lebowitz

Because every biotech and medtech professional knows that Jerusalem BioCity consistently delivers world-class programming, the best professionals always show up and the networking before and after the events is worth its time in gold.

– Moshe Lebowitz, CEO, Healables Digital Health | Healables: Wearables that Heal

JLM-BioCity was recently written up in THE MARKER (in Hebrew). To see the article, click here.

Alexander Naslednikov

Tal Or

Hemda Idel

Aviv Marom

Aurélie Schwarzbach

Zeev Malyutin

Gideon Silberman

Immanuel Lerner

Dror Chevion

Ian Solomon

Moshe Lebowitz

Strategic Partners

Platinum

Gold

Silver

Contact us at

Follow us

Copyright © 2020 JLM-BioCity | All rights reserved